(Q34965532)

5 August 2017

1 reference

title

Pharmacogenetics: from discovery to patient care (English)

1 reference

5 August 2017

1 reference

Jaekyu Shin

1

1 reference

PubMed ID

19299369

5 August 2017

Steven R Kayser

series ordinal

2

1 reference

PubMed ID

19299369

5 August 2017

Taimour Y Langaee

series ordinal

3

1 reference

5 August 2017

1 April 2009

1 reference

American Journal of Health-System Pharmacy

5 August 2017

1 reference

5 August 2017

66

1 reference

5 August 2017

625-637

1 reference

5 August 2017

7

1 reference

Putting pharmacogenetics into practice

5 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Global variation in copy number in the human genome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

CYP2D6 phenotype prediction from genotype: which system is the best?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Identification of the gene for vitamin K epoxide reductase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Pharmacogenetics of beta-blockers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genetic approaches to polycystic ovarian syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

On the interpretation of genetic association studies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

The candidate gene approach to susceptibility for abdominal aortic aneurysm: TIMP1, HLA-DR-15, ferritin light chain, and collagen XI-Alpha-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genome-wide association studies: theoretical and practical concerns

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

High-resolution haplotype structure in the human genome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Evaluating and improving power in whole-genome association studies using fixed marker sets.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Complement factor H polymorphism in age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

LDL-cholesterol concentrations: a genome-wide association study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genomewide association analysis of coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Risk alleles for multiple sclerosis identified by a genomewide study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Drinking from the fire hose--statistical issues in genomewide association studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era...

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

A marker for Stevens-Johnson syndrome ...: ethnicity matters

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Pharmacogenetics of irinotecan toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Letting the genome out of the bottle--will we get our wish?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Adding pharmacogenetics information to drug labels: lessons learned

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Oversight of US genetic testing laboratories

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Molecular genetic testing in the United States: comparison with international practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genetic testing for warfarin dosing? Not yet ready for prime time

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Pharmacogenetics and irinotecan therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genotyping systems for drug-metabolizing enzymes go clinical

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Where are we headed: the value of updating guidelines.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Educating health-care professionals about genetics and genomics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

Pharmacogenetic testing: not as simple as it seems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080170

31 March 2020

Identifiers

DOI

10.2146/AJHP080170

1 reference

5 August 2017

1 reference

PubMed ID

19299369